Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCORD: ALXN2030 in antibody-mediated rejection after kidney transplantation
2024-517498-25-00Phase 2Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in humoral rejection comparing ALXN2030 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Biopsy-proven histologic resolution at Week 52. Planned start Jan 2026; status: authorised.
02
Drugs
ALXN2030
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2024-517498-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517498-25-00.